Gluz, O.; Nitz, U.; Christgen, M.; Kates, R.; Clemens, M.; Kraemer, S.; Nuding, B.; Aktas, B.; Kuemmel, S.; Reimer, T.; Lorenz-Salehi, F.; Krabisch, P.; Just, M.; Augustin, D.; Liedtke, C.; Svedman, C.; Shak, S.; Wuerstlein, R.; Kreipe, H. und Harbeck, N.
(2016):
Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer.
In: European Journal of Cancer, Bd. 57:
S6-S6
Volltext auf 'Open Access LMU' nicht verfügbar.
- Dokument bearbeiten
